Prosecution Insights
Last updated: August 16, 2026
Application No. 17/594,367

SMALL MOLECULE SCREENING CELLULAR ASSAY USING MODIFIED BEADS

Non-Final OA §112
Filed
Oct 13, 2021
Priority
Apr 16, 2019 — EU 19169563.4 +1 more
Examiner
YOUNG, BRIAN ELLIS
Art Unit
1684
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hoffmann-La Roche Inc.
OA Round
2 (Non-Final)
66%
Grant Probability
Favorable
2-3
OA Rounds
0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
23 granted / 35 resolved
+5.7% vs TC avg
Strong +30% interview lift
Without
With
+30.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
22 currently pending
Career history
63
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
35.8%
-4.2% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
28.7%
-11.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 35 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions 2. Applicant's election with traverse of Group II, claims 11-15, in the reply filed on 18 June 2025 is acknowledged. The traversal is on the grounds that the full scope of the invention could be searched and examined without undue burden on the patent office. This is not found persuasive because restriction requirements for 371 national stage applications are not predicated on undue burden related to search and examination, but rather there must be a special technical feature unifying the different inventive concepts in view of the prior art. No such special technical feature was found, see the remarks starting on pg. 4 of the restriction requirement dated 22 April 2025. The requirement is still deemed proper and is therefore made FINAL. Claim Rejections - 35 USC § 112 3. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 4. Claims 11-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A. Regarding claim 11, the phrase “in particular polystyrene” renders the claim indefinite because it is unclear whether the limitations following this phrase are part of the claimed invention. See MPEP § 2173.05(d). B. Claims 12-15 are rejected as they are dependent on rejected claim 11. Allowable Subject Matter 5. Claims 11-15 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. 6. The following is a statement of reasons for the indication of allowable subject matter: Applicant’s amendment’s to the claims have overcome the prior art rejections outlined in the Office Action filed 12 August 2025. See applicant’s remarks, filed 25 November 2025, pg. 10 ¶ 2. Conclusion 7. No claims are allowed. 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN ELLIS YOUNG whose telephone number is (703)756-5397. The examiner can normally be reached M-F 0730 - 1700. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heather Calamita can be reached at (571) 272-2876. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN ELLIS YOUNG/Examiner, Art Unit 1684 /JULIET C SWITZER/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Oct 13, 2021
Application Filed
Aug 12, 2025
Non-Final Rejection mailed — §112
Nov 25, 2025
Response Filed
Nov 25, 2025
Applicant Interview (Telephonic)
Mar 27, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12680097
METHODS FOR INCREASING YIELD OF SEQUENCING LIBRARIES
5y 1m to grant Granted Jul 14, 2026
Patent 12674158
METHODS FOR DNA LIBRARY GENERATION TO FACILITATE THE DETECTION AND REPORTING OF LOW FREQUENCY VARIANTS
4y 9m to grant Granted Jul 07, 2026
Patent 12668793
SEQUENTIAL ENCODING METHODS AND RELATED KITS
4y 10m to grant Granted Jun 30, 2026
Patent 12631624
METHODS FOR ISOLATING SURFACE MARKER DISPLAYING AGENTS
5y 0m to grant Granted May 19, 2026
Patent 12630875
METHODS FOR RAPID DNA EXTRACTION FROM TISSUE AND LIBRARY PREPARATION FOR NANOPORE-BASED SEQUENCING
4y 8m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
66%
Grant Probability
96%
With Interview (+30.1%)
3y 10m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 35 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month